vs
Side-by-side financial comparison of Duolingo, Inc. (DUOL) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Duolingo, Inc. is the larger business by last-quarter revenue ($295.5M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Duolingo, Inc. runs the higher net margin — 11.9% vs 1.6%, a 10.2% gap on every dollar of revenue. On growth, Duolingo, Inc. posted the faster year-over-year revenue change (27.0% vs 5.0%). Over the past eight quarters, Duolingo, Inc.'s revenue compounded faster (28.7% CAGR vs -0.2%).
Duolingo, Inc. is a leading global edtech firm operating a gamified language learning platform. It offers free and premium self-paced courses for over 40 languages, plus language certification, math learning tools, and literacy programs, serving individual learners, schools and corporate clients worldwide.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
DUOL vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.5M | $177.4M |
| Net Profit | $35.1M | $2.9M |
| Gross Margin | 55.5% | — |
| Operating Margin | 8.0% | 3.9% |
| Net Margin | 11.9% | 1.6% |
| Revenue YoY | 27.0% | 5.0% |
| Net Profit YoY | 24.0% | — |
| EPS (diluted) | $0.72 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.5M | $177.4M | ||
| Q4 25 | $282.9M | $196.9M | ||
| Q3 25 | $271.7M | $179.5M | ||
| Q2 25 | $252.3M | $181.1M | ||
| Q1 25 | $230.7M | $168.9M | ||
| Q4 24 | $209.6M | $187.3M | ||
| Q3 24 | $192.6M | $168.6M | ||
| Q2 24 | $178.3M | $178.0M |
| Q1 26 | $35.1M | $2.9M | ||
| Q4 25 | $42.0M | — | ||
| Q3 25 | $292.2M | $5.4M | ||
| Q2 25 | $44.8M | $-4.8M | ||
| Q1 25 | $35.1M | $4.8M | ||
| Q4 24 | $13.9M | — | ||
| Q3 24 | $23.4M | $-143.5M | ||
| Q2 24 | $24.4M | $18.9M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 72.8% | 79.5% | ||
| Q3 25 | 72.5% | 80.9% | ||
| Q2 25 | 72.4% | 77.4% | ||
| Q1 25 | 71.1% | 79.7% | ||
| Q4 24 | 71.9% | 78.7% | ||
| Q3 24 | 72.9% | 76.9% | ||
| Q2 24 | 73.4% | 75.1% |
| Q1 26 | 8.0% | 3.9% | ||
| Q4 25 | 15.4% | 1.2% | ||
| Q3 25 | 12.9% | 3.5% | ||
| Q2 25 | 13.2% | 4.7% | ||
| Q1 25 | 10.2% | 1.2% | ||
| Q4 24 | 6.6% | 13.2% | ||
| Q3 24 | 7.0% | -82.8% | ||
| Q2 24 | 10.5% | 15.9% |
| Q1 26 | 11.9% | 1.6% | ||
| Q4 25 | 14.8% | — | ||
| Q3 25 | 107.5% | 3.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 15.2% | 2.8% | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 12.1% | -85.1% | ||
| Q2 24 | 13.7% | 10.6% |
| Q1 26 | $0.72 | $0.07 | ||
| Q4 25 | $0.99 | $0.05 | ||
| Q3 25 | $5.95 | $0.12 | ||
| Q2 25 | $0.91 | $-0.11 | ||
| Q1 25 | $0.72 | $0.10 | ||
| Q4 24 | $0.31 | $0.38 | ||
| Q3 24 | $0.49 | $-3.11 | ||
| Q2 24 | $0.51 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $653.9M |
| Total Assets | $2.0B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | $144.3M | ||
| Q4 25 | $1.0B | $238.4M | ||
| Q3 25 | $1.0B | $246.3M | ||
| Q2 25 | $976.2M | $445.9M | ||
| Q1 25 | $884.0M | $493.6M | ||
| Q4 24 | $785.8M | $484.6M | ||
| Q3 24 | $854.4M | $453.8M | ||
| Q2 24 | $888.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.3B | $653.9M | ||
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.3B | $727.2M | ||
| Q2 25 | $977.0M | $757.8M | ||
| Q1 25 | $893.8M | $798.5M | ||
| Q4 24 | $824.5M | $778.3M | ||
| Q3 24 | $822.5M | $749.6M | ||
| Q2 24 | $766.9M | $879.3M |
| Q1 26 | $2.0B | $1.2B | ||
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.3B | $1.6B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $105.6M | — |
| Free Cash FlowOCF − Capex | $103.0M | — |
| FCF MarginFCF / Revenue | 34.9% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $368.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $105.6M | — | ||
| Q4 25 | $107.3M | $43.7M | ||
| Q3 25 | $84.2M | $60.8M | ||
| Q2 25 | $90.7M | $12.0M | ||
| Q1 25 | $105.6M | $35.5M | ||
| Q4 24 | $83.3M | $33.1M | ||
| Q3 24 | $56.3M | $53.9M | ||
| Q2 24 | $62.4M | $53.2M |
| Q1 26 | $103.0M | — | ||
| Q4 25 | $96.6M | $43.5M | ||
| Q3 25 | $79.4M | $57.0M | ||
| Q2 25 | $89.5M | $9.3M | ||
| Q1 25 | $104.3M | $26.9M | ||
| Q4 24 | $81.4M | $31.0M | ||
| Q3 24 | $53.1M | $49.8M | ||
| Q2 24 | $56.8M | $51.6M |
| Q1 26 | 34.9% | — | ||
| Q4 25 | 34.1% | 22.1% | ||
| Q3 25 | 29.2% | 31.7% | ||
| Q2 25 | 35.5% | 5.1% | ||
| Q1 25 | 45.2% | 15.9% | ||
| Q4 24 | 38.8% | 16.6% | ||
| Q3 24 | 27.6% | 29.6% | ||
| Q2 24 | 31.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 0.1% | ||
| Q3 25 | 1.8% | 2.2% | ||
| Q2 25 | 0.5% | 1.5% | ||
| Q1 25 | 0.6% | 5.1% | ||
| Q4 24 | 0.9% | 1.1% | ||
| Q3 24 | 1.7% | 2.4% | ||
| Q2 24 | 3.1% | 0.9% |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.56× | — | ||
| Q3 25 | 0.29× | 11.20× | ||
| Q2 25 | 2.02× | — | ||
| Q1 25 | 3.01× | 7.37× | ||
| Q4 24 | 5.99× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 2.56× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DUOL
| Bookings | $283.5M | 96% |
| Other | $12.0M | 4% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
